Home
Contact Palatin
Site Map
.
.
.
.
.
.
Investor/Media Center
Overview
Press Releases
Event Calendar
Webcasts
SEC Filings
Analyst Coverage
Corporate Governance
Investor Materials
Corporate Fact Sheet
Investor Materials
Management bios
For Institutional Investors and Media:
Carney Noensie
Burns McClellan
(212) 213-0006
cnoensie@burnsmc.com
Press Releases:
May-14-2013
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
May-08-2013
Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
May-02-2013
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
Mar-19-2013
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
Mar-15-2013
PALATIN TECHNOLOGIES TO PRESENT AT THE 25TH ANNUAL ROTH CONFERENCE
Mar-04-2013
PALATIN TECHNOLOGIES, INC. TO PRESENT AT THE COWEN & COMPANY 33rd ANNUAL HEALTH CARE CONFERENCE
Mar-01-2013
Palatin Technologies Presents Positive Data for Bremelanotide in Female Sexual Dysfunction
Feb-14-2013
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
Overview
Press Releases
Event Calendar
Webcasts
SEC Filings
Analyst Coverage
Corporate Governance
Investor Materials
Overview
Executive Management
Board of Directors
Overview
Career Opportunities
Overview
Press Releases
Presentations
Events Calendar
Webcasts
Media Kit
Overview
PL-3994 for CHF
PL-3994 for Asthma
PL-3994 for Hypertension
Bremelanotide
PL-6983
Obesity
Overview
Licensing and Collaboration Opportunities